One of such hallmarks is the overexpression of HER2 that occurs in 15–20% of breast cancers that are diagnosed, and also in other types of solid tumors, such as gastric, ovarian, or lung carcinomas [3,4,5,91]. This evidence concerns the gene ERBB2 and lung carcinoma.